Table 4.

Comparison of difference in gene expression between combination treatment and mono-treatment in PC-3 and LNCaP cells

GeneDocetaxel + Estramustine
6h36h72h
Decrease in combination treatment in PC-3 cells, No change or increase in mono-treatment
    U63131 CDC37 homologue, proliferation-relatedNC−2.1−1.6
    NM_012121 Cdc42 effector protein 4 (CEP4), proliferation-related−2.1NCNC
    NM_002006 fibroblast growth factor 2 (basic; FGF2), proliferation-related1.9−2.1−2
    NM_005627 serum glucocorticoid-regulated kinase (SGK), proliferation-related1.6−1.6−2.3
    U78525 eukaryotic translation initiation factor (eIF3), proliferation-relatedNC−1.5−2
    BC001173 eukaryotic translation initiation factor 3, proliferation-relatedNC−1.6−2
    NM_001814 cathepsin C (CTSC), invasion-relatedNC−1.5−2
    NM_002532 nucleoporin 88 kDa (NUP88), oncogenesis-relatedNC−2−1.9
    NM_003155 stanniocalcin 1 (STC1), oncogenesis-related−1.5−1.6−2.1
    NM_002774 kallikrein 6 (neurosin, zyme; KLK6), oncogenesis-related−1.1−1.9−2
    NM_001216 carbonic anhydrase IX (CA9), oncogenesis-related−2.31.7NC
    L78132 prostate carcinoma tumor antigen (pcta-1), oncogenesis-related−2NCNC
    NM_001145 angiogenin, ribonuclease, RNase A family, 5 (ANG), angiogenesis-related−2.6NCNC
    NM_001038 sodium channel, nonvoltage-gated 1α (SCNN1A), cell size and shape-related−2.1NC1.7
Increase in combination treatment in PC-3 cells, no change or decrease in mono-treatment
    AI056359 microtubule-associated protein, differentiation-related1.72.64.9
    X79683 laminin, β2, differentiation-related1.121.9
    AI812030 thrombospondin 1, angiogenesis-related2.1−1.9−2.5
    NM_000396 cathepsin K (pycnodysostosis; CTSK), invasion-relatedNC23.5
    AA020826 cathepsin B, invasion-related1.122
    M99422 glutathione transferase (GST), drug resistance-related1.11.62.1
    X08020 glutathione S-transferase subunit 4, drug resistance-relatedNC1.62
    M21940.1 cytochrome P450 S-mephenytoin 4-hydroxylase (P-450mp), drug resistance-related1.11.92
    M15331 cytochrome P450 S-mephenytoin 4-hydroxylase (P-450mp), drug resistance-related1.72.32.3
Decrease in combination treatment in LNCaP cells, no change or increase in mono-treatment
    NM_003461 zyxin (ZYX), proliferation-related−2.0−1.1NC
    AF274954 PNAS-29, proliferation-related−1.1−1.6−2.0
    NM_007034 heat shock protein 40 (HLJ1), stress-related−1.7−2.1−2.1
    BG403660 heat shock 105 kDa, stress-relatedNC−1.9−2.0
Increase in combination treatment in LNCaP cells, no change or decrease in mono-treatment
    U02520.1 collagen type IV 3, differentiation-related1.22.12.3
    NM_020348 cyclin M1 (CNNM1), proliferation-related2.32.01.9
    BF197655 caveolin 2, oncogenesis-related2.3−2.02.8
    NM_001657 amphiregulin (AREG), apoptosis-related4.35.34.0
    M33987 carbonic anhydrase I (CAI), metastasis-related2.63.23.2
    NM_000928 phospholipase A2, group IB (pancreas; PLA2G1B), oncogenesis-related11.33.07.5
    NM_004039 annexin A2 (ANXA2, drug resistance-related2.02.62.3
    X08020.1 glutathione S-transferase subunit 4, drug resistance-related1.12.11.6
    NM_014139 sodium channel, voltage-gated, type XII, (SCN12A), cell size and shape-related2.56.13.2
  • NOTE: NC, no change; negative values, decrease; positive values, increase (P < 0.05).